SIA
JAZZ icon

Starfire Investment Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History

Starfire Investment Advisers’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,350
Closed -$201K – 158
2019
Q4 		$201K Buy
+1,350
New +$184K 0.08% 169
2015
Q4 		– Sell
-3,300
Closed -$438K – 133
2015
Q3 		$438K Hold
3,300
– – 0.32% 76
2015
Q2 		$581K Hold
3,300
– – 0.38% 63
2015
Q1 		$570K Buy
+3,300
New +$566K 0.37% 65

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Starfire Investment Advisers's JAZZ Position: Q1 2020 in Review

Starfire Investment Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 1,350 shares — an estimated $201K sold.

Starfire Investment Advisers first reported a position in JAZZ in Q1 2015 and held it in 4 quarters. The position peaked at $581K in Q2 2015. 408 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

  • Starfire Investment Advisers reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Starfire Investment Advisers sold 1,350 Jazz Pharmaceuticals shares in Q1 2020, an estimated $201K.
  • Starfire Investment Advisers first reported a position in Jazz Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Starfire Investment Advisers's Jazz Pharmaceuticals position peaked at $581K in Q2 2015.
  • 408 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Starfire Investment Advisers's 13F filing for Q1 2020, filed 14 Apr 2020.